Search Results
Center for Ingestive Behavior Research, University at Buffalo, Buffalo, New York, USA
Search for other papers by Katherine N Balantekin in
Google Scholar
PubMed
Search for other papers by Martin J Kretz in
Google Scholar
PubMed
Center for Ingestive Behavior Research, University at Buffalo, Buffalo, New York, USA
Search for other papers by Elizabeth G Mietlicki-Baase in
Google Scholar
PubMed
options that cause fewer side effects, to decrease the act of binge eating. The glucagon-like peptide 1 (GLP-1) system has become an area of intense research focus due to its ability to reduce food intake and body weight in humans and non-human animals
Search for other papers by Shou-Si Lu in
Google Scholar
PubMed
Search for other papers by Yun-Li Yu in
Google Scholar
PubMed
Search for other papers by Hao-Jie Zhu in
Google Scholar
PubMed
Search for other papers by Xiao-Dong Liu in
Google Scholar
PubMed
Search for other papers by Li Liu in
Google Scholar
PubMed
Search for other papers by Yao-Wu Liu in
Google Scholar
PubMed
Search for other papers by Ping Wang in
Google Scholar
PubMed
Search for other papers by Lin Xie in
Google Scholar
PubMed
Search for other papers by Guang-Ji Wang in
Google Scholar
PubMed
play is an important role in the regulation of endocrine pancreatic secretion. The intestinal products of the proglucagon gene, glucagon-like peptide-1 (GLP-1), has been shown to contribute significantly to the overall insulin response to oral glucose
Search for other papers by Antonella Amato in
Google Scholar
PubMed
Search for other papers by Sara Baldassano in
Google Scholar
PubMed
Search for other papers by Rosa Liotta in
Google Scholar
PubMed
Search for other papers by Rosa Serio in
Google Scholar
PubMed
Search for other papers by Flavia Mulè in
Google Scholar
PubMed
Introduction Glucagon-like peptide 1 (GLP1), produced by intestinal enteroendocrine L-cells in response to the ingestion of nutrients ( Schirra et al . 1996 ), is highly insulinotropic and an inhibitor of gastrointestinal motility, effects that
Search for other papers by Sara Baldassano in
Google Scholar
PubMed
Search for other papers by Anna Lisa Bellanca in
Google Scholar
PubMed
Search for other papers by Rosa Serio in
Google Scholar
PubMed
Search for other papers by Flavia Mulè in
Google Scholar
PubMed
Introduction Glucagon-like peptide 2 (GLP2) is a 33-amino acid peptide, produced by the processing of the proglucagon gene within the mucosal L-cells of the intestine and specific neurons located in the brainstem. The actions of GLP2 are transduced
Search for other papers by Sara Baldassano in
Google Scholar
PubMed
Search for other papers by Antonella Amato in
Google Scholar
PubMed
Search for other papers by Francesco Cappello in
Google Scholar
PubMed
Search for other papers by Francesca Rappa in
Google Scholar
PubMed
Search for other papers by Flavia Mulè in
Google Scholar
PubMed
, including the proglucagon-derived peptides, glucagon-like peptide-1 (GLP1), and GLP2, and there is evidence for a link among GLP2, intestinal growth, and increased energy intake ( Xiao et al . 1999 , Shin et al . 2005 , Nelson et al . 2008 ). GLP2 is a
Search for other papers by Guillaume Mabilleau in
Google Scholar
PubMed
Search for other papers by Marie Pereira in
Google Scholar
PubMed
Search for other papers by Chantal Chenu in
Google Scholar
PubMed
needed, to reach an HbA 1C level of 7% or less. Among the most prescribed drugs, the glucagon-like peptide-1 receptor agonists (GLP-1RAs) have recently attracted attention as Glp-1r -knockout animals, and GLP-1-supplemented animals exhibited
Search for other papers by Jennifer A Crookshank in
Google Scholar
PubMed
Search for other papers by Daniel Serrano in
Google Scholar
PubMed
Search for other papers by Gen-Sheng Wang in
Google Scholar
PubMed
Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada
Search for other papers by Christopher Patrick in
Google Scholar
PubMed
Department of Biomedical Sciences, University of Ottawa, Ottawa, Ontario, Canada
Search for other papers by Baylie S Morgan in
Google Scholar
PubMed
Search for other papers by Marie-France Paré in
Google Scholar
PubMed
Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada
Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada
Search for other papers by Fraser W Scott in
Google Scholar
PubMed
proteins were used: insulin (Agilent Technologies Canada Inc., Mississauga, Canada), proinsulin (Bio-Techne, Minneapolis, USA), glucagon (MilliporeSigma), BIP (Abcam Inc.). ImageJ (National Institute of Health) was used to quantify the insulin + and
et d'Analyses Microscopiques (SCIAM), School of Biomedical Sciences
Groupe d'Etudes sur le Remodelage Osseux et les bioMatériaux (GEROM) – LHEA, Service Commun d'Imageries
et d'Analyses Microscopiques (SCIAM), School of Biomedical Sciences
Search for other papers by Guillaume Mabilleau in
Google Scholar
PubMed
et d'Analyses Microscopiques (SCIAM), School of Biomedical Sciences
Search for other papers by Aleksandra Mieczkowska in
Google Scholar
PubMed
et d'Analyses Microscopiques (SCIAM), School of Biomedical Sciences
Search for other papers by Nigel Irwin in
Google Scholar
PubMed
et d'Analyses Microscopiques (SCIAM), School of Biomedical Sciences
Search for other papers by Peter R Flatt in
Google Scholar
PubMed
et d'Analyses Microscopiques (SCIAM), School of Biomedical Sciences
Groupe d'Etudes sur le Remodelage Osseux et les bioMatériaux (GEROM) – LHEA, Service Commun d'Imageries
et d'Analyses Microscopiques (SCIAM), School of Biomedical Sciences
Search for other papers by Daniel Chappard in
Google Scholar
PubMed
al . 2010 ). Glucagon-like peptide-1 (GLP1) is a gut hormone synthesized and secreted into the blood stream by intestinal endocrine L cells in response to a variety of stimuli ( Wu et al . 2010 ). Biologically active GLP1 is secreted as a 7–37 or 7
Tsukuba Research Institute, Division of Integrative Physiology, Banyu Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki 300-2611, Japan
Search for other papers by Jun-ichi Eiki in
Google Scholar
PubMed
Search for other papers by Kaori Saeki in
Google Scholar
PubMed
Search for other papers by Norihiro Nagano in
Google Scholar
PubMed
Search for other papers by Tomoharu Iino in
Google Scholar
PubMed
Search for other papers by Mari Yonemoto in
Google Scholar
PubMed
Search for other papers by Yoko Takayenoki-Iino in
Google Scholar
PubMed
Search for other papers by Satoru Ito in
Google Scholar
PubMed
Search for other papers by Teruyuki Nishimura in
Google Scholar
PubMed
Search for other papers by Yoshiyuki Sato in
Google Scholar
PubMed
Search for other papers by Makoto Bamba in
Google Scholar
PubMed
Search for other papers by Hitomi Watanabe in
Google Scholar
PubMed
Search for other papers by Kaori Sasaki in
Google Scholar
PubMed
Search for other papers by Sumika Ohyama in
Google Scholar
PubMed
Search for other papers by Akio Kanatani in
Google Scholar
PubMed
Search for other papers by Toshio Nagase in
Google Scholar
PubMed
Search for other papers by Toshihiko Yada in
Google Scholar
PubMed
Introduction Glucagon-like peptide-1 (GLP-1) is a hormone secreted from enteroendocrine L-cells, and is well recognized as an incretin that induces insulin secretion in a glucose-dependent manner ( Drucker 2006 ). The functions of GLP-1 have been
Search for other papers by Leila Arbabi in
Google Scholar
PubMed
Search for other papers by Qun Li in
Google Scholar
PubMed
Search for other papers by Belinda A Henry in
Google Scholar
PubMed
Search for other papers by Iain J Clarke in
Google Scholar
PubMed
on GnRH secretion. Amongst other hormones, that regulate GnRH secretion, glucagon-like peptide-1 (GLP-1) from the gut and/or the brain has been shown to stimulate GnRH secretion, although the pathway for such an effect has not been elucidated. This